Evidence map›Paper›PMID 38159292›Full record

ArticleACS chemical biology2024

Novel Substrate Prediction for the TAM Family of RTKs Using Phosphoproteomics and Structure-Based Modeling.

Naomi E Widstrom, Grigorii V Andrianov, Jason L Heier, Celina Heier, John Karanicolas, Laurie L Parker

Open access · greenAbstract read
In one paragraph

Article in ACS chemical biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Naomi E WidstromDepartment of Biochemistry, Molecular Biology and Biophysics, College of Biological Sciences, University of Minnesota Twin Cities, Minneapolis, Minnesota 55455, United States.ORCID 0000-0003-3669-5732
Grigorii V AndrianovCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, United States.
Jason L HeierDepartment of Biochemistry, Molecular Biology and Biophysics, College of Biological Sciences, University of Minnesota Twin Cities, Minneapolis, Minnesota 55455, United States.
Celina HeierDepartment of Biochemistry, Molecular Biology and Biophysics, College of Biological Sciences, University of Minnesota Twin Cities, Minneapolis, Minnesota 55455, United States.
John KaranicolasCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, United States.ORCID 0000-0003-0300-726X
Laurie L ParkerDepartment of Biochemistry, Molecular Biology and Biophysics, College of Biological Sciences, University of Minnesota Twin Cities, Minneapolis, Minnesota 55455, United States.ORCID 0000-0002-6234-3346
University of Minnesota · USFox Chase Cancer Center · US

Funding

WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Dietmar J Kappes · 1985 to 2026
$138.8M
TRAINING GRANT IN MICROBIOLOGY/CANCER RESEARCHT32CA009138 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Scott M. Dehm · 1985 to 2026
$11.3M
Designing selective kinase inhibitors via deep learningR01GM141513 · NIGMS · RESEARCH INST OF FOX CHASE CAN CTR · PI RINK, LORI · 2022 to 2025
$2.4M
Biosensor Assay to Screen for Signaling Pathway Inhibition in CancerR01CA182543 · NCI · UNIVERSITY OF MINNESOTA · PI PARKER, LAURIE L. · 2014 to 2018
$2.1M
Multiplexed proteomics-based kinase assay developmentR01GM146386 · NIGMS · UNIVERSITY OF MINNESOTA · PI PARKER, LAURIE L. · 2022 to 2025
$1.5M
NCI NIH HHS P30 CA006927NCI NIH HHS R01 CA182543NCI NIH HHS T32 CA009138NIGMS NIH HHS R01 GM141513NIGMS NIH HHS R01 GM146386
6 · The paper itself

Abstract

The TAM family of receptor tyrosine kinases is implicated in multiple distinct oncogenic signaling pathways. However, to date, there are no FDA-approved small molecule inhibitors for the TAM kinases. Inhibitor design and screening rely on tools to study the kinase activity. Our goal was to address this gap by designing a set of synthetic peptide substrates for each of the TAM family members: Tyro3, Axl, and Mer. We used an in vitro phosphoproteomics workflow to determine the substrate profile of each TAM kinase and input the identified substrates into our data processing pipeline, KINATEST-ID, producing a position-specific scoring matrix for each target kinase and generating a list of candidate synthetic peptide substrates. We synthesized and characterized a set of those substrate candidates, systematically measuring their initial phosphorylation rate with each TAM kinase by LC-MS. We also used the multimer modeling function of AlphaFold2 (AF2) to predict peptide-kinase interactions at the active site for each of the novel candidate peptide sequences against each of the TAM family kinases and observed that, remarkably, every sequence for which it predicted a putative catalytically competent interaction was also demonstrated biochemically to be a substrate for one or more of the TAM kinases. This work shows that kinase substrate design can be achieved using a combination of preference motifs and structural modeling, and it provides the first demonstration of peptide-protein interaction modeling with AF2 for predicting the likelihood of constructive catalytic interactions.

Indexed as

Axl Receptor Tyrosine KinaseProto-Oncogene ProteinsFurylfuramidePeptidesReceptor Protein-Tyrosine KinasesAxl Receptor Tyrosine KinaseFurylfuramidePeptidesProto-Oncogene ProteinsReceptor Protein-Tyrosine Kinases

Identifiers

PMID38159292
PMCPMC10921923
OpenAlexW4390439776

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.